Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesANI Pharmaceuticals Inc

ANI Pharmaceuticals Inc

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
68.05 USD 0.64 ( 0.95%)
Last update at 2026-11-09T15:45:00Z
VOLUME
34095
Market Cap
1818.65M
P/E
24.60

Momentum Score

…

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
67.45
Low
68.40
High
52 Week Price Range
56.71
Low
99.50
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

ANI Pharmaceuticals develops and markets generic and specialty pharmaceutical products and provides finished-dose manufacturing and contract services. Long-term growth may be driven by product approvals, expanded contract-manufacturing revenue, targeted acquisitions and commercialization of higher-margin specialty offerings. Investors may find it attractive for its manufacturing footprint, niche product mix and potential for steady cash flow from commercial assets. Key investment risks include regulatory and approval delays, generics pricing pressure, product concentration, integration risk from acquisitions and supply-chain or quality issues that could hurt sales and margins.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
67.41
Dividend Yield
-
Revenue TTM
883.37M
Revenue Per Share
44.05
Gross Profit TTM
542.06M
Debt / Equity
0.60
ROE
16.16%
Net Debt
39.61M
ROCE
9.97%
Diluted EPS TTM
3.25

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 95.79M -22.21M 19.87M -62.66M -56.06M
Net income 78.34M -18.52M 18.78M -47.90M -42.60M
Selling general administrative 317.75M 249.64M 150.42M 127.80M 84.29M
Gross profit 450.64M 364.17M 305.30M 177.60M 115.53M
Reconciled depreciation 91.42M 67.73M 60.17M 56.97M 47.25M
Ebit 115.85M -4.61M 46.81M -25.06M -32.51M
Ebitda 207.27M 63.12M 106.60M 31.91M 14.74M
Depreciation and amortization 91.42M 67.73M 59.79M 56.97M 47.25M
Non operating income net other - - - 0.67M -4.34M
Operating income 81.23M 0.58M 46.97M -25.06M -32.51M
Other operating expenses 802.14M 613.79M 439.85M 342.12M 244.31M
Interest expense 20.06M 17.60M 26.94M 28.05M 11.92M
Tax provision 17.45M -3.69M -0.18M -14.77M -13.46M
Net interest income -20.06M -17.60M -28.70M -28.05M -11.92M
Non recurring - - - 5.79M 11.12M
Income tax expense 17.45M -3.69M 1.09M -14.77M -13.46M
Total revenue 883.37M 614.38M 486.82M 316.38M 216.14M
Total operating expenses 369.41M 363.58M 258.33M 203.33M 143.69M
Cost of revenue 432.73M 250.21M 181.51M 138.78M 100.61M
Total other income expense net 14.56M -22.80M -27.10M -37.60M -23.55M
Net income from continuing ops 78.34M -18.52M 13.38M -47.90M -42.60M
Net income applicable to common shares - - - -49.52M -42.79M
Preferred stock and other adjustments - - - 1.62M 0.19M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1440.38M 1283.70M 904.42M 760.09M 771.60M
Intangible assets 479.53M 541.83M 209.01M 251.63M 294.12M
Other current assets 43.38M 18.01M 25.22M 8.39M 11.26M
Total liab 899.65M 855.17M 471.67M 421.55M 412.86M
Total stockholder equity 540.72M 428.53M 432.75M 338.54M 358.74M
Deferred long term liab - - - 0.60M 0.80M
Other current liab 187.23M 132.10M 99.78M 69.28M 63.63M
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 24.85M 24.85M 24.85M 24.85M
Retained earnings -23.10M -100.28M -80.13M -97.29M -47.77M
Other liab - - - 35.06M 31.02M
Good will 62.48M 59.99M 28.22M 28.22M 27.89M
Other assets - - - 92.72M 75.14M
Cash 285.58M 144.86M 221.12M 48.23M 100.30M
Total current liabilities 278.11M 193.68M 145.48M 99.44M 87.54M
Current deferred revenue - - 8.16M - 0.09M
Net debt 39.61M 479.23M 94.21M 238.29M 187.07M
Short term debt 17.27M 9.17M 0.85M 0.85M 0.85M
Short long term debt 17.27M 9.17M 0.85M 0.85M 0.85M
Short long term debt total 325.19M 624.09M 315.33M 286.52M 287.37M
Other stockholder equity 562.79M 498.61M 479.17M 398.81M 384.71M
Property plant equipment - - - 43.25M 52.67M
Total current assets 753.12M 527.68M 519.62M 344.26M 321.77M
Net tangible assets - - - 58.68M 36.73M
Short term investments 9.13M 6.31M - - -
Net receivables 281.08M 221.73M 162.08M 165.44M 128.53M
Long term debt 599.77M 614.92M 284.82M 285.67M 286.52M
Inventory 143.07M 136.78M 111.20M 105.36M 81.69M
Accounts payable 62.58M 45.66M 36.68M 29.30M 22.97M
Accumulated other comprehensive income 1.03M 5.34M 8.86M 12.17M -3.06M
Common stock total equity - - - 0.00M 0.00M
Retained earnings total equity - - - -97.29M -47.77M
Non currrent assets other 13.71M 12.22M 6.07M 11.36M 7.21M
Non current assets total 687.26M 756.01M 384.81M 415.83M 449.82M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -404.72M -16.87M -15.74M -105.48M
Change to liabilities - - - 4.88M 2.59M
Total cashflows from investing activities -34.32M -404.72M -18.51M -15.74M -105.48M
Net borrowings -10.16M 345.22M -3.00M -3.00M 99.02M
Total cash from financing activities -9.94M 264.94M 67.44M -5.13M 194.59M
Change to operating activities - - - 4.36M -0.35M
Net income 78.34M -18.52M 18.78M -47.90M -42.60M
Change in cash 140.73M -76.23M 167.89M -52.07M 92.43M
Begin period cash flow 144.89M 221.12M 53.23M 105.30M 12.87M
End period cash flow 285.62M 144.89M 221.12M 53.23M 105.30M
Total cash from operating activities 185.22M 64.02M 118.96M -31.20M 3.32M
Issuance of capital stock 0.00M 0.00M 80.56M 0.00M 100.00M
Depreciation 91.42M 67.73M 59.79M 59.65M 47.25M
Other cashflows from investing activities -34.32M 12.80M -9.64M -6.86M -102.93M
Dividends paid 1.16M 1.62M 1.62M -1.62M -0.19M
Change to inventory -5.96M -21.29M -5.84M -23.63M 3.22M
Change to account receivables -58.53M -21.09M 3.36M -36.91M -5.55M
Sale purchase of stock -12.21M -10.96M -4.99M -1.96M -0.89M
Other cashflows from financing activities -0.03M -67.69M -3.50M 1.46M 331.69M
Change to netincome - - - 0.32M -3.75M
Capital expenditures 13.84M 16.95M 18.51M 16.45M 23.64M
Change receivables - - - -36.91M -5.55M
Cash flows other operating - - - 8.42M -0.35M
Cash and cash equivalents changes - - - -52.07M 92.43M
Change in working capital -7.12M -11.19M 24.86M -51.30M -0.08M
Stock based compensation 37.93M 29.34M 20.65M 14.60M 10.49M
Other non cash items -29.57M 18.56M 6.62M 8.99M 5.02M
Free cash flow 171.39M 47.06M 100.45M -47.66M -20.32M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ANIP
ANI Pharmaceuticals Inc		 0.64
0.95%		 68.05 24.60 9.28 2.06 3.44 2.47 10.53
MKKGY
Merck KGaA ADR		 0.49
1.48%		 33.66 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -2.76
1.62%		 167.12 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR		 -0.05
0.24%		 20.97 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 0.50
1.19%		 42.35 - 10.66 0.01 1.16 2.94 23.11

Profile*

ANI Pharmaceuticals Inc

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

210 Main Street West, Baudette, MN, United States, 56623

218 634 3500

https://www.anipharmaceuticals.com

970

Name Title Year Born
Mr. Nikhil Lalwani Pres, CEO & Director 1978
Mr. Stephen P. Carey CFO, Sr. VP of Fin. & Corp. Sec. 1971
Mr. James G. Marken Sr. VP of Operations & Product Devel. 1963
Mr. Christopher K. Mutz Head of Rare Disease 1972
Mr. Ori Gutwerg Sr. VP of Generics 1974
Mr. Muthusamy Shanmugam MS R.Ph. Head of R&D, COO of Novitium Operations & Director 1968
Ms. Meredith W. Cook Sr. VP, Gen. Counsel & Corp. Sec. NA
Mr. Chad Gassert Sr. VP of Corp. Devel. & Strategy 1976
Ms. Krista L. Davis Chief HR Officer NA
Ms. Elizabeth Powell J.D. Chief Compliance Officer & Head of Legal of Rare Disease NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.93
+37.83%
MOON
CAD 4.86
+10.20%
HG
CAD 4.43
+9.93%
EPRX
CAD 10.57
+8.86%
NUAG
CAD 8.66
+8.79%
CSU
CAD 3257.60
-7.63%
DIV
CAD 3.85
-5.53%
TOI
CAD 99.00
-5.52%
BSX
CAD 0.82
-4.65%
LMN
CAD 26.79
-4.63%

Equity Sectors*

  • Basic Materials

    +3.88%

  • Communication Services

    -1.14%

  • Consumer Cyclical

    +0.75%

  • Consumer Defensive

    -0.36%

  • Energy

    +2.16%

  • Financial Services

    +1.33%

  • Healthcare

    +1.50%

  • Industrials

    +2.97%

  • Real Estate

    +0.41%

  • Technology

    +1.27%

  • Utilities

    +1.09%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…